Skip to main content
Jordan Schecter, MD, Hematology, Raritan, NJ

Jordan Mark Schecter MD

Hematology•Raritan, NJ

Hematologic Oncology

VP Cellular Therapy

Join to View Full Profile

  • 920 US-202 SRaritan, NJ 08869

  • Phone+1 908-927-3159

Dr. Schecter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Schecter's Full ProfileAlready have an account?

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2007
  • Rhode Island Hospital/Brown University Health
    Rhode Island Hospital/Brown University HealthInternship, Internal Medicine, 2004 - 2005
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 2004

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2006 - 2027

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...
    Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
    Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Authored Content

  • Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021

Press Mentions

  • Investigational Combination of First-in-Class Bispecifics TALVEY® and TECVAYLI® Shows Deep and Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease
    Investigational Combination of First-in-Class Bispecifics TALVEY® and TECVAYLI® Shows Deep and Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary DiseaseJune 15th, 2025
  • Single Infusion of CARVYKTI® (Ciltacabtagene Autoleucel) Delivered Lasting Treatment-Free Remissions for at Least Five Years in Patients with Relapsed or Refractory Multiple Myeloma
    Single Infusion of CARVYKTI® (Ciltacabtagene Autoleucel) Delivered Lasting Treatment-Free Remissions for at Least Five Years in Patients with Relapsed or Refractory Multiple MyelomaJune 3rd, 2025
  • DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)-Based Regimen Shows 95 Percent Progression-Free Survival at Four Years in Transplant-Eligible, Newly Diagnosed Patients with Multiple Myeloma Who Achieved Sustained MRD Negativity
    DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)-Based Regimen Shows 95 Percent Progression-Free Survival at Four Years in Transplant-Eligible, Newly Diagnosed Patients with Multiple Myeloma Who Achieved Sustained MRD NegativityJune 3rd, 2025
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Jordan Schecter, Dr. Jordan Schecter, MD, Dr. J Schecter, Dr. Jordan Mark Schecter